Launch of TASECTAN® AF in Finland and Sweden
Following the launch of TASECTAN® AF in Denmark in August, Pharmaforce has just marketed this product also in Finland (September) and Sweden (October). Last April,
Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland and Norway.
Noventure grants Pharmaforce exclusive distribution right for its product Tasectan® AF in the countries Denmark, Sweden, Finland, and Norway. Tasectan® AF is intended to restore
New publication for Utipro® Plus
New publication for Utipro® Plus We are pleased to announce the publication of a case series referring about the benefits of Utipro® Plus in some
Utipro® Plus Webinar session
We are pleased to inform you about our first #webinar sessions❗ On October 30th we talked about #UTIPROPLUS and its use in uncomplicated #UTIs. Some
A new publication confirms the role of xyloglucan as a mucosa protector in the management of urinary tract infections
Esposito E et al. Effect of xyloglucan against Escherichia coli extraintestinal urinary tract infection: an in vivo study. Microb Physiol. Published online: Oct 16, 2020.
Urinary tract infections in the elderly: a review of disease characteristics and current treatment options
Rodriguez-Mañas L. Urinary tract infections in the elderly: a review of disease characteristics and current treatment options. Drugs in Context 2020; 9: 2020-4-13. DOI: 10.7573/dic.2020-4-13.
Xyloglucan, hibiscus and propolis to reduce symptoms and antibiotics use in recurrent UTIs: a prospective study.
Cai T et al. Xyloglucan, hibiscus and propolis to reduce symptoms and antibiotics use in recurrent UTIs: a prospective study. Future Microbiol. 2019 Aug;14:1013-1021. doi:
Utipro® Plus AF available for launch
Utipro® Plus AF available for launch We are pleased to announce the availability for launch of a new formulation of UTIPRO® PLUS, our product for
UTIPRO PLUS® launched in Finland
We are pleased to announce the launch of UTIPRO® PLUS, our product for uncomplicated UTIs, in Finland. The product is commercialized over the Finnish territory
News on NOVENTURE participation at EAU 2019 in BARCELONA
News on NOVENTURE participation at EAU 2019 in BARCELONA For the fourth consecutive year, Noventure was present at the annual congress of the EAU –
